BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

July 23, 2012 7:00 AM UTC

Active Biotech AB (SSE:ACTI) gained SEK6.05 (14%) to SEK50.25 on Tuesday after EMA accepted for review an MAA for laquinimod to treat relapsing-remitting multiple sclerosis. The acceptance triggered a $5 million payment to Active from Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), which has exclusive, worldwide rights. For the week, Active Biotech was up SEK3.50 to SEK47.30. Teva gained $1.23 to $41.61.

Ophthalmic company Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.09 to $3.02 last week after announcing French regulatory approval of Iluvien for chronic diabetic macular edema (DME) and plans to raise $40 million through the sale of 1 million units at $40 per unit...